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http://dxObjectives:Aortic valve regurgitation reduces left ventricular assist device mechanical efficiency. Evidence has
also suggested that left ventricular assist device implantation can induce or exacerbate aortic valve regurgitation.
However, this has not been compared with aortic valve regurgitation progression in a nonsurgical end-stage heart
failure population. Furthermore, its clinical effect is unclear.We sought to characterize the development and pro-
gression of aortic valve regurgitation in left ventricular assist device recipients and to identify its clinical effect.
Methods: A review of all consecutive patients who received an intracorporeal left ventricular assist device at
Duke University Medical Center from January 2004 to January 2011 was conducted. Cases of previous or con-
comitant aortic valve surgery were excluded. Data from the remaining implants (n¼ 184) and a control group of
contemporaneous nonsurgical patients with end-stage heart failure (n¼ 132) were analyzed. Serial transthoracic
echocardiography was used to characterize aortic valve regurgitation as a function of time.
Results: Left ventricular assist device implantation was associated with worsening aortic valve regurgitation,
defined as an increase in aortic valve regurgitation grade, relative to the nonsurgical patients with end-stage heart
failure (P<.0001). The recipients of continuous flow left ventricular assist devices were more likely than re-
cipients of pulsatile left ventricular assist devices to develop worsening aortic valve regurgitation
(P ¼ .0348). Moderate or severe aortic valve regurgitation developed in 21 left ventricular assist device recip-
ients; this was unrelated to the type of device implanted (continuous vs pulsatile; P ¼ .754) or aortic valve re-
gurgitation grade before left ventricular assist device implantation (P ¼ .42). Five patients developed severe
aortic valve regurgitation; all of whom underwent aortic valve procedures.
Conclusions: Native aortic valve regurgitation developed and/or progressed after left ventricular assist device
implantation, with this effect being more pronounced in continuous flow left ventricular assist device recipients.
However, the preoperative aortic valve regurgitation grade failed to correlatewith the development of substantial
aortic valve regurgitation after left ventricular assist device implantation. After left ventricular assist device im-
plantation, aortic valve regurgitation had a small, but discernible, clinical effect, with some patients developing
severe aortic valve regurgitation and requiring aortic valve procedures. These data have implications for the
long-term management of left ventricular assist device recipients, in particular as the durability of implantable
continuous flow left ventricular assist device therapy improves. (J Thorac Cardiovasc Surg 2013;145:1373-9)End-stage heart failure (ESHF) refractory to maximal phar-
macologic therapies is an increasingly prevalent problem in
the United States and worldwide. ESHF treatment is largely
surgical and generally by cardiac transplantation (CT) and
implantation of left ventricular (LV) assist devices
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Xof the limitations in the donor organ supply, a small fraction
of all patients with ESHF undergo CT. Thus, with the cur-
rent technology level, chronic implantable LVAD therapy
likely represents the most widely applicable ESHF treat-
ment strategy. Consistent with this, in the United States,
the annual number of LVAD implants is approaching the an-
nual number of CTs.1
Despite its obvious benefits, LVAD therapy has several
limitations. Of these, progression of aortic valve (AV) re-
gurgitation (AR) might substantially effect the physiology
and clinical outcomes of LVAD recipients. It is widely rec-
ognized that substantial AR recognized at LVAD implanta-
tion should be addressed surgically to prevent the loss of
LVAD mechanical efficiency that AR would otherwise
cause.2,3 AR results in a requirement for an excessive
total left-sided output to maintain the constancy of a normal
net antegrade left-sided output, with the difference between
the 2 equaling the regurgitant flow rate. In the LVADdiovascular Surgery c Volume 145, Number 5 1373
Abbreviations and Acronyms
AR ¼ aortic valve regurgitation
AVR ¼ AV replacement
AV ¼ aortic valve
cfLVAD ¼ continuous flow LVAD
CT ¼ cardiac transplantation
ESHF ¼ end-stage heart failure
HF ¼ heart failure
LV ¼ left ventricular
LVAD ¼ left ventricular assist device
LVIDd ¼ LV diastolic dimensions
NS-ESHF ¼ nonsurgical ESHF
pfLVAD ¼ pulsatile flow LVAD
TTE ¼ transthoracic echocardiography
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Xrecipient, this generally results in greater device work and
flow rate for the systemic output to be normal.
A range of treatment strategies, including AV repair using
various techniques,4 AV replacement (AVR) with biologic
prostheses,5 AV closure, or left ventricular outflow tract
patching,6,7 and percutaneous transcatheter techniques,8,9
have been successfully implemented. In addition, it is now
increasingly appreciated that LVAD therapy can cause AV
damage as a function of time,10,11 resulting in de novo
and/or progressive AR, which, in turn, could adversely
affect the mechanical efficiency of the LVAD. Two recent
studies12,13 have echocardiographically characterized the
development and progression of post-LVAD implantation
AR. These 2 studies suggested that patients with a continu-
ous flow LVAD (cfLVAD) had more rapid progression of
AR relative to patients supported with pulsatile flow LVADs
(pfLVAD). In addition, greater pump speeds and larger aor-
tic root dimensions were associated with greater progres-
sion of AR. In addition, a recent study has reviewed
a large series of LVAD recipients who required either con-
comitant or delayed AV procedures because of AR, with 8
patients having undergone post-LVAD implantation AV
procedures at concomitant LVAD exchange.6 However,
the echocardiographic and invasive hemodynamic charac-
teristics of AR in these patients were not reported, and
whether AR was a predominant contributor to heart failure
(HF) in these patients is not clear. Therefore, we sought to
characterize the development and progression of post-
LVAD implantation AR relative to a nonsurgical HF control
group and to examine its clinical effect.
METHODS
Patients and Surgical Procedures
The study groups were composed of patients treated at Duke University
Medical Center from January 2004 to January 2011. The LVAD recipient
group (n ¼ 184) included pfLVAD (n ¼ 36) and cfLVAD (n ¼ 148) recip-
ients. Patients in the pfLVAD group underwent implantation of the Thora-
tec HeartMate XVE device (n ¼ 33; Thoratec, Pleasanton, Calif) or the1374 The Journal of Thoracic and Cardiovascular SurNovacor LVAD (n ¼ 3; Novacor, Oakland, Calif). Patients in the cfLVAD
group underwent implantation with the Thoratec HeartMate II (n ¼ 139),
HeartWare HVAD (n ¼ 6), or Ventracor VentrAssist (n ¼ 3) device. In pa-
tients treated withmore than 1 LVAD, the attribution of ARwasmade to the
device in place when AR progressed. Patients who underwent concomitant
or previous AV surgery were excluded from the study. The nonsurgical
ESHF (NS-ESHF) group (n ¼ 132) included contemporaneous patients
who did not undergo LVAD implantation. The NS-ESHF group all under-
went evaluation at the advanced HF clinic at Duke UniversityMedical Cen-
ter from 2005 to 2010. The diagnostic evaluation to assess ESHF included
transthoracic echocardiography (TTE), right-sided cardiac catheterization,
and cardiopulmonary exercise testing. In both LVAD and NS-ESHF
groups, the patients who underwent CT were censored at CT.
Assessment of AR
Serial TTE assessments were performed in both patient groups. Base-
line studies were performed before LVAD implantation. Postimplantation
assessments were performed as clinically indicated, rather than at sched-
uled intervals. AR was graded using standard American Society of Echo-
cardiography criteria14 translated into a specific grade: none or trivial
(grade 0), mild (grade 1), moderate (grade 2), moderate-to-severe (grade
3), and severe (grade 4). Progression was defined as an increase in AR
grade of 1 grade or more. Our protocol for determining LVAD speed set-
tings during the study period was to achieve optimal LV unloading, with
characteristic TTE findings of normal LV dimensions, neutral septal posi-
tion, and typically persistent AV closure. Greater pump speeds that resulted
in leftward septal distortion and LV collapse were avoided. This strategy
was consistent with the study by Amin and colleagues,15 who first demon-
strated that septal distortion and LV collapse occurred at even greater
cfLVAD speeds than those required to induce persistent AV closure.
Data Collection and Statistical Analysis
The institutional review board approved the study, and individual pa-
tient consent was waived. Data were collected in a post hoc fashion from
a review of the clinically generated patient care documentation. Data
were analyzed using R, version 2.15.0 GUI 1.51 Leopard build 64-bit
(6148; R Foundation for Statistical Computing, Vienna, Austria).16 Contin-
uous covariates are reported as the median and interquartile range. Categor-
ical variables are reported as proportions. Continuous covariates were
compared using the Wilcoxon rank sum test or Kruskal-Wallis test, as ap-
propriate. Categorical covariates were compared using the Fisher exact test
or chi-square test, as appropriate. Survival and failure curves were gener-
ated using the Kaplan-Meier method.16,17 The survival and failure curves
were compared using the log-rank test.RESULTS
Patient Characteristics
The characteristics of the NS-ESHF and LVAD recipient
groups are listed in Table 1. The LVAD recipients had more
severe LV systolic dysfunction, as assessed by the LVejec-
tion fraction. In addition, a greater percentage of LVAD re-
cipients had an ischemic/postmyocardial infarction etiology
relative to theNS-ESHF group. Finally, the LVAD recipients
were older than their NS-ESHF counterparts. The median
duration of LVAD support, total LVAD patient years for
the cfLVAD and pfLVAD groups, median interval to echo-
cardiographic follow-up for all 3 groups, and total echocar-
diographic follow-up in patient years for both groups are
also listed in Table 1. As anticipated, the duration of support
and the interval to the follow-up echocardiogram weregery c May 2013
TABLE 1. Patient characteristics
Characteristic
NS-ESHF
(n ¼ 132)
LVAD
(n ¼ 184)
cfLVAD
(n ¼ 148)
pfLVAD
(n ¼ 36)
P value
NS-ESHF vs LVAD
NS-ESHF vs cfLVAD
and pfLVAD
Age (y)
Median 52 58 59 52 <.0001 .0002
Interquartile range 40-60 46-68 46-68 48-61
Gender (n) .6046 .0028
Male 95 138 103 35
Female 37 46 45 1
Etiology (n) <.0001 .001
Ischemic/post-MI 34 69 54 15
Idiopathic 56 52 46 6
Valvular 1 4 3 1
Congenital 1 1 1 0
Mixed ischemic/post-MI 21 21 17 4
Mixed, nonischemic 19 37 27 10
LVEF (%)
Median 20 10 10 10 <.0001 <.0001
Interquartile range 15-30 10-20 10-20 10-22.5
LVAD duration (d)
Median 308 371 83.5
Interquartile range 56-722 89-796 42-252
Total (pt-y) 231.2 208.1 23.1
Interval to echocardiographic
follow-up (d)
Median 843 220 243 68.5
Interquartile range 272-1912 21-314 18-364 31-157
Total follow-up (pt-y) 483.9 111.1 98.5 12.6
NS-ESHF, Nonsurgical end-stage heart failure; LVAD, left ventricular assist device; cfLVAD, continuous flow LVAD; pfLVAD, pulsatile flow LVAD; MI, myocardial infarction;
LVEF, left ventricular ejection fraction.
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Xconsiderably longer for the cfLVAD than for the pfLVAD
group. The medical therapy control group had longer
follow-up relative to the combined LVAD group.
Development and Progression of Post-LVAD
Implantation AR
Serial TTE was used to assess the development and pro-
gression of AR (defined as an increase in AR grade of 1 or
more, which would thus include new-onset AR) in the
LVAD and NS-ESHF groups. LVAD implantation was asso-
ciated with an increased rate of the development and
progression of AR relative to the nonsurgical controls
(P<.0001; Figure 1, A). The control group displayed virtu-
ally no AR progression during the follow-up period. AR
progression was more rapid after cfLVAD implantation
than after pfLVAD implantation (P ¼ .0348; Figure 1, B).
We hypothesized that clinically important ARwould be at
least moderate in severity. Thus, we assessed the develop-
ment of moderate or worse AR over time in the LVAD and
NS-ESHFgroups. Freedomfrommoderate or greaterARde-
creased over time in the LVAD group (Figure 2, A). This re-
sult was statistically significant (P< .0001). However, no
difference was found in the freedom from moderate or
greater AR between the cfLVAD and pfLVAD subgroupsThe Journal of Thoracic and Car(P ¼ .754; Figure 2, B). Also, freedom from moderate AR
was unrelated to the preimplantation AR grade (P ¼ .42;
Table 2). This finding might have been a consequence of
an institutional preference for treating moderate or greater
AR identified at LVAD implantation with a concomitant
AV procedure (see the ‘‘Discussion’’ section). Finally, pa-
tient survival divided by the development of moderate or
greater AR is shown in Figure 3. This statistically equivalent
survival might have resulted from the smaller number of pa-
tientswith progression to severeARwhounderwent success-
ful surgical reoperation to correct the AR. Furthermore, the
overall small number of patients in the moderate and severe
AR group also limited the power of the survival analysis.
Patients With Moderate or Worse AR
Within the LVAD group, 21 patients (19 cfLVAD and 2
pfLVAD) developed moderate or greater AR during the
study period. Of these 21 patients, 16 had moderate AR
and 5 developed severe AR (see the next section). Patients
with moderate or greater AR, however, demonstrated effec-
tive mechanical unloading, with LV diastolic dimensions
(LVIDd) that were within the normal range (mean LVIDd
before LVAD, 6.9  1.0 cm vs mean LVIDd after LVAD,
5.3  1.2 cm; P<.0001). One patient with moderate ARdiovascular Surgery c Volume 145, Number 5 1375
FIGURE 1. A, Freedom from progression of aortic valve regurgitation
(AR) in nonsurgical patients with end-stage heart failure (NS-ESHF) versus
all left ventricular assist device (LVAD) recipients. B, Freedom from pro-
gression of AR for pulsatile flow (pfLVAD) versus continuous flow
(cfLVAD) LVAD recipients.
FIGURE 2. A, Freedom from moderate or severe aortic valve regurgita-
tion (AR) in nonsurgical patients with end-stage heart failure (NS-ESHF)
versus all left ventricular assist device (LVAD) recipients. B, Freedom
from moderate to severe AR for pulsatile flow (pfLVAD) versus continuous
flow (cfLVAD) LVAD recipients.
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Xand pfLVAD dysfunction underwent CT. However, no other
patients with moderate AR developed clinical HF or were
deemed to require AV surgery.
Severe AR
Five cfLVAD patients developed severe AR. All five had
recurrent HF symptoms, and, after a thorough evaluation,
all five underwent AV procedures. One patient underwent
AV repair with concomitant LVAD exchange because of
suspected intradevice thrombus. This patient was later suc-
cessfully bridged to CT. At the last follow-up examination,1376 The Journal of Thoracic and Cardiovascular Surshe was alive and well. A second patient underwent percu-
taneous AV closure using an Amplatzer occluder device;
however, the device migrated retrograde into the LV cavity
and threatened to occlude apical LVAD inflow. That patient
underwent an emergent attempted AV repair that failed in-
traoperatively with residual AR, requiring AVR with
a 19-mm St Jude Biocor Supra valve (St Jude Medical, St
Paul, Minn). At the last follow-up visit, he was alive and
well, continuing with LVAD support. A third patient was di-
rectly bridged to CTand was also doing well approximately
4 years after CT. A fourth patient developed severe AR lessgery c May 2013
TABLE 2. Characteristics of LVAD recipients
Characteristic
Moderate
or worse
AR (n ¼ 21)
Less than
moderate
AR (n ¼ 164)
P
value
Age (y) .848
Median 58 59
Interquartile range 44-69 47-67
Gender (n) .0599
Male 12 126
Female 9 38
Etiology (n) .8106
Ischemic/post-MI 7 62
Idiopathic 6 46
Valvular 1 3
Congenital 0 1
Mixed, ischemic/post-MI 2 20
Mixed, nonischemic 5 32
LVEF (%) .8857
Median 10 10
Interquartile range 10-25 10-20
Preoperative AR grade (n) .42
None 11 99
Mild 8 37
Moderate 2 19
LVAD, Left ventricular assist device; AR, aortic valve regurgitation; MI, myocardial
infarction; LVEF, left ventricular ejection fraction.
Rajagopal et al Cardiothoracic Transplantationthan 1 month after LVAD implantation and was admitted to
the hospital with shock and multiorgan system dysfunction.
She underwent urgent AVR with a 19-mm St Jude Biocor
Supra valve, tricuspid valve repair with a 27-mm St Jude
Tailor annuloplasty ring for severe tricuspid valve regurgi-
tation, and concomitant LVAD exchange because of pumpFIGURE 3. Survival over time for left ventricular assist device (LVAD)
recipients with progression to either moderate or severe aortic valve regur-
gitation (AR) versus those with less than moderate AR.
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after surgery secondary to renal and hepatic failure. The
fifth patient recently underwent AVR with a 19-mm St
Jude Trifecta valve with concomitant LVAD exchange ow-
ing to an ascending driveline infection. At her last follow-up
visit, she was recovering well.
DISCUSSION
Most patientswith ESHFwill not undergoCT.The reasons
for this are, principally, the lack of adequate donor organ
availability, and the relatively stringent recipient criteria
that exclude patients with many common comorbidities or
advanced age. Thus, mechanical circulatory support as
long-term or ‘‘destination therapy’’ is the best treatment op-
tion formost patientswithESHF.With the increasingdurabil-
ity and longevity of cfLVADs, attention has focused on the
management of long-term LVAD complications, including
AR, right ventricular dysfunction, hemorrhagic and thrombo-
embolic complications, and device-related infections.
The development and progression of AR in LVAD recipi-
ents is not well understood. Previous reports11-13 have
established significant associations between LVAD
implantation and the development of AR; however, these
studies did not include nonsurgical HF control groups. In the
present report, we have demonstrated that LVAD therapy is
associated with the development and progression of AR
relative to the natural history of patients with ESHF not
treated with implantable LVADs. Our use of a nonsurgical
HF group allowed for a rigorous assessment of the
contributions of LVADs to AR development and progression
over time. Minimal AR progression was evident in the
nonsurgical HF group.
It is challenging to predict the circumstances under which
AR will occur after LVAD implantation. Our data did not
identify an association between preoperative AR grade
and the development of moderate or greater postoperative
AR. Some patients with preoperative moderate or severe
AR underwent concomitant AV procedures at LVAD im-
plantation and were censored. Thus, a putative association
between the preoperative AR grade and the development
of moderate or greater AR might not have been identified
owing to the exclusion of some patients with preoperative
moderate or worse AR that might have progressed even fur-
ther after LVAD implantation. Nonetheless, the lack of a de-
monstrable association between the preoperative and
postoperative AR grades underscores the importance of se-
rial AV surveillance after LVAD implantation.
AR development or progression was more pronounced in
the cfLVAD recipients, consistent with the findings from
previous studies.12,13 AR might progress more rapidly
after cfLVAD implantation owing to the constant and
more complete LV unloading, resulting in a persistently
closed or minimally mobile native AV. The lack of normal
cyclic AV motion might then result in leaflet fibrosis ordiovascular Surgery c Volume 145, Number 5 1377
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although AR assessed by imaging studies might appear
worse after LVAD implantation, with greater regurgitant
flow rates, the regurgitant fraction (the regurgitant flow
rate, or regurgitant volume per unit time, divided by the
total left-sided flow rate or cardiac output) might not be sub-
stantially changed early after LVAD implantation. The
trans-AV regurgitant flow rate in the setting of a well-
functioning LVAD is determined by the systemic mean
(instead of diastolic in the native circulation) arterial pres-
sure, the intracavitary LV pressure, and the impedance of
the AV to retrograde flow. The regurgitant flow rate is caus-
ally dependent on the aorta–LV pressure difference. How-
ever, the aorta–LV pressure difference is a function
dependent on the LVAD pump speed and impedance or
afterload of the systemic circulation, for an assumed fixed
left-sided preload. Thus, the regurgitant flow rate is gener-
ally proportional to the total LVAD output, although the na-
ture of this relationship is affected by the systemic afterload.
The complex relationships between the LV and aortic
pressure, systemic circuit impedance/resistance, trans-
LVAD and transnative AV antegrade and retrograde flow
challenge the accurate prediction of the effect of post-
LVAD implantation AR. Our findings suggest that AR
progresses as a function of time and is likely related to alter-
ations in the trans-AV pressure gradient combined with
a dysfunctional, minimally mobile, or immobile AV. New
moderate or greater AR developed in 11.4% of the LVAD
recipients in our cohort. However, all patients in that group
maintained LV unloading, with a mean LVIDd well less
than the current American College of Cardiology/American
Heart Association guideline criteria for surgical AVR for
AR.18 Additionally, a comprehensive study from the Uni-
versity of Michigan13 actually correlated AR with smaller
LV chamber dimensions. If post-LVAD implantation AR
was physiologically important, the LV chamber dimensions
should not be reduced, because volume unloading of the left
ventricle should be difficult to achieve.
The present study did not try to define the treatment strat-
egies for LVAD patients who experience significant AR. It is
possible that medical treatment and pump speed adjustments
could alter the rate ofARdevelopment or progression.We ac-
knowledge that most of our patients had pump speeds set to
achieve LV unloading, with infrequent opening of the AV.
Furthermore, significant pumpspeed alterationswerenot per-
formed for patients who developed AR. The most consistent
medical intervention was systemic blood pressure reduction
for those patients who presented with new AR and hyperten-
sion. Significant differences in medical management and
pumpspeed adjustmentmight alterARprogression and could
lead to inconsistent findings among different centers.
Although we did find that patients with moderate or
greater ARmaintained LV volume unloading, 5 of these pa-
tients (2.7% of the total) developed severe AR and clinical1378 The Journal of Thoracic and Cardiovascular SurHF, all of whom underwent AV procedures that were, ulti-
mately, open reoperations. The 4 survivors had clinical im-
provement after these procedures. The nonsurviving patient
was in extremis on hospital readmission. Thus, when severe
AR does occur after LVAD implantation, we believe that re-
operation can be undertaken safely and using an open ap-
proach. Although percutaneous strategies have been used
to treat AR in LVAD recipients, it is unclear whether
such approaches yield equivalent outcomes to reoperative
surgery.
Finally, our data did not identify an association between
moderate or greater AR and diminished survival outcomes.
This was in part owing to the generally favorable outcomes
for the 5 patients with severe AR who underwent reopera-
tion. The need for major cardiac reoperation for these 5
patients represented significant added morbidity.CONCLUSIONS
Post-LVAD implantation AR remains a challenging en-
tity to understand, anticipate, and treat. More long-term
studies are required to better determine the physiologic
and clinical effect of AR in this rapidly expanding subpop-
ulation of patients with ESHF.References
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